The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Superiority of ibutilide (a new class III agent) overdl-sotalol in converting atrial flutter and atrial fibrillation
Open accessAbstract
OBJECTIVE: To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol in terminating chronic atrial fibrillation or flutter in haemodynamically stable patients. DESIGN: Double blind, randomised study. SETTING: 43 European hospitals. PATIENTS: 308 patients (mean age 60 years, 70% men, 48% with heart disease) with sustained atrial fibrillation (n = 251) or atrial flutter (n = 57) (duration three hours to 45 days) were randomised to three groups to receive a 10 minute infusion of 1 mg ibutilide (n = 99), 2 mg ibutilide (n = 106), or 1.5 mg/kg DL-sotalol (n = 103). Infusion was discontinued at termination of the arrhythmia. MAIN OUTCOME MEASURE: Successful conversion of atrial fibrillation or flutter, defined as termination of arrhythmia within one hour of treatment. RESULTS: Both drugs were more effective against atrial flutter than against atrial fibrillation. Ibutilide was superior to DL-sotalol for treating atrial flutter (70% and 56% v 19%), while the high dose of ibutilide was more effective for treating atrial fibrillation than DL-sotalol (44% v 11%) and the lower dose of ibutilide (44% v 20%, p < 0.01). The mean (SD) time to arrhythmia termination was 13 (7) minutes with 2 mg ibutilide, 19 (15) minutes with 1 mg ibutilide, and 25 (17) minutes with DL-sotalol. In all patients, the duration of arrhythmia before treatment was a predictor of arrhythmia termination, although this was less obvious in the group that received 2 mg ibutilide. This dose converted almost 48% of atrial fibrillation that was present for more than 30 days. Concomitant use of digitalis or nifedipine and prolongation of the QTc interval were not predictive of arrhythmia termination. Bradycardia (6.5%) and hypotension (3.7%) were more common side effects with DL-sotalol. Of 211 patients given ibutilide, two (0.9%) who received the higher dose developed polymorphic ventricular tachycardia, one of whom required direct current cardioversion. CONCLUSION: Ibutilide (given in 1 or 2 mg doses over 10 minutes) is highly effective for rapidly terminating persistent atrial fibrillation or atrial flutter. This new class III drug, under monitored conditions, is a potential alternative to currently available cardioversion options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dofetilide and ibutilide, pure class III AADs, are very effective for interrupting AFL in intravenous administration, while Class Ia and Ic drugs have little or no effect.138 -142,149”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial Fibrillation Begets Atrial Fibrillation
WIJFFELS, M. C. E. F., Kirchhof, C. J. H. J., Dorland, R., & Allessie, M. A. (1995) · Circulation · doi:10.1161/01.cir.92.7.1954 · Cited by 3,500
Rensma, P., Allessie, M., Lammers, W., Bonke, F. I., & Schalij, M. (1988) · Circulation Research · doi:10.1161/01.res.62.2.395 · Cited by 686
Stambler, B. S., Wood, M. A., Ellenbogen, K. A., Perry, K. T., Wakefield, L. K., & VanderLugt, J. T. (1996) · Circulation · doi:10.1161/01.cir.94.7.1613 · Cited by 485
Self-citationEllenbogen, K. A., Stambler, B. S., Wood, M. A., Sager, P. T., Wesley, R. C., Meissner, M. D., Zoble, R. G., Wakefield, L. K., Perry, K. T., VanderLugt, J. T., et al. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00121-0 · Cited by 370
Self-citationDigoxin for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm
Falk, R. H., Knowlton, A. A., Bernard, S. A., Gotlieb, N. E., & Battinelli, N. J. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-503 · Cited by 335
SUTTORP, M. J., Kingma, J. H., JESSURUN, E. R., Lie‐A‐Huen, L., van Hemel, N. M., & Lie, K. I. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)90326-k · Cited by 282
Colatsky, T. J., Follmer, C. H., & Starmer, C. F. (1990) · Circulation · doi:10.1161/01.cir.82.6.2235 · Cited by 256
Atrial Fibrillation Begets Atrial Fibrillation
Lu, Z., Scherlag, B. J., Lin, J., Niu, G., Fung, K.-M. A., Zhao, L., Ghias, M., Jackman, W. M., Lazzara, R., Jiang, H., et al. (2008) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.108.784272 · Cited by 247
Carlsson, L. G., Almgren, O., & Duker, G. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199008000-00014 · Cited by 236
Falk, R. H., Pollak, A., Singh, S. N., & Friedrich, T. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00506-2 · Cited by 215
Research works printed but not linked: 3
- Volgman, 1996, Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter [abstract]., PACE, 19, 169
- Bianconi, 1995, Comparison of intravenously administered dofetilide versus amiodarone in the acute conversion of atrial fibrillation and flutter. A multicenter, randomized, double-blind, placebo controlled study [abstract]., Circulation, 92, 774
- 10.1161/01.CIR.92.7.1954 · DOI
Cited by
Sorted by citations
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,823
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A. M., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 3,145
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,929
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Metadata
- Authors
- Vos, M. A., Golitsyn, S. R., Stangl, K., Ruda, M. Y., Van Wijk, L., Harry, J. D., Perry, K. T., Touboul, P., Steinbeck, G., & Wellens, H. J. J.
- Affiliations
- Refaja Ziekenhuis (NL)
- aUniversity Hospital, Maastricht, Netherlands, bCardiology Research Centre, Moscow, Russia, cHumholdt University, Berlin, Germany, dSt Chr Ziekenhuis Refaja, Stadskanaal, Netherlands, ePharmacia & Upjohn, Crawley, West Sussex, UK, fPharmacia & Upjohn, Kalamazoo, Michigan, USA, gHospitaux de Lyon, Lyon, France, hKlinikum Grosehadern of the University of Munich, Germany
- Corresponding author
- Vos, M A
- Venue
- Heart
- Publisher
- BMJ
- Published
- 1998-06-01
- Volume
- 79
- Issue
- 6
- Pages
- 568-575
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- PMC
- PMC1728725
- OpenAlex
- W2129291556
- Cited by
- 200
- References
- 39
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 5 · 2018: 2 · 2017: 9 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 4 · 2012: 4
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Heart (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- class III antiarrhythmic agents, atrial fibrillation, atrial flutter, drug safety, bradycardia, hypotension, QTc prolongation, digitalis, nifedipine
- MeSH terms
- Adult, Aged, Aged, 80 and over, Analysis of Variance, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Double-Blind Method, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Prospective Studies, Sotalol, Sulfonamides, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
